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INTRODUCTION 
Jaundice in pregnancy carries a grave prognosis and is responsible 
for 10% of maternal deaths. Abnormal liver function test occur in 3% to 
5% of Pregnancy.  
The causes may be  
1) Co-incidental –viral Hepatitis, Gall stones.  
2) Underlying chronic liver disease – cirrhosis, portal 
hypertension,chronic viral hepatitis, cholestatic jaundice. 
3) Pregnancy related  
i) Associated with Pre eclampsia:- 
 Preeclampsia  
 HELLP syndrome 
 Acute fatty liver of pregnancy 
ii) Without pre eclampsia :  
 Hyperemesis gravidarum 
 Intrahepatic cholestasis of pregnancy  
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4) Physiological changes during pregnancy – 
Abnormal liver function test may occur as physiological 
change in pregnancy. 
In developing countries like India, there is high mortality and 
morbidity in jaundice complicating pregnancy is due to associated factors 
like lack of awareness, poor hygiene and sanitation,malnutrition, 
anaemia, unbooked cases, late referral in moribund condition.  
The common cause of death is due to Hepatic encephalopathy, 
shock,disseminated intravascular coagulation, renal failure, postpartum 
haemorrhage.  
The aim of this study is to analyse the various causes for jaundice 
in pregnancy, the factors affecting its course and to determine the 
outcome of pregnancy among the pregnant women treated at Government 
Coimbatore Medical College and Hospital, Coimbatore.  
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AIMS AND OBJECTIVES 
 
 To study the incidence and distribution of jaundice in relation to 
age, parity, socio economic status and duration of pregnancy.  
 To study the relation of serum bilirubin levels to maternal 
mortality. 
 To assess the severity of maternal outcome in terms of maternal 
mortality and morbidity. 
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ANATOMY OF LIVER 
 
Liver is the largest exocrine gland in the body weighing about 1.5 
kg in an average adult weighing about 70 kg. This is located in the right 
hypochondrium and a part of epigastric region.  
 Liver is attached to the anterior abdominal wall and the diaphragm 
by four distinctive ligaments:  
1. Coronary ligament which connects the posterior surface of the right  
hepatic lobe to the diaphragm with a superior and an inferior layer 
between that lies in the bare area of the liver; 
2. Right triangular ligament which is formed by fusion of the superior 
and inferior layers of the coronary ligament;  
3. Left triangular ligament which connects the posterior surface of the 
left lobe of the liver to the diaphragm  
4. Falciform ligament which extends from the diaphragm and anterior 
wall above the level of the umbilicus to the surface of the liver, 
where it divides the left hepatic lobe into the left lateral and left 
medial segments 
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Liver segment is divided into eight segments . COUINAUD coined a 
system for liver segmental nomenclature  (8 segments). Liver is divided 
into segments by a longitudinal planes drawn through each hepatic vein 
to the vena cava and a transverse plane at the level of the main portal 
bifurcation .Cantlie’s line marks the course of the middle hepatic vein  
 
Fig. 1. Segments of Liver 
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BLOOD SUPPLY 
The two sources that supply blood to the liver  are Hepatic artery 
and portal vein. Hepatic artery is a branch from celiac trunk of aorta . 
Portal vein is formed by the confluence of the superior mesenteric vein 
and the splenic vein at the level of the second lumbar vertebra behind the 
head of pancreas . It supplies about  75% of the total liver blood supply 
by volume. 
Blood exits the liver via the central vein accounting for  25% of 
cardiac output. Blood flow into the liver is controlled by number of 
factors like Muscular sphincters ,  autonomic nervous system, circulating 
hormones, bile salts, and metabolites . 
VENOUS DRAINAGE 
Majority of the venous drainage of the liver occurs through three 
hepatic veins . Right hepatic vein drains the segments 6,7,8 and enters 
directly into the vena cava.   
 Middle hepatic vein drains segments 5 and  inferior part of segment 
4 . Left hepatic vein  drains the segments 2,3 and superior part of 4.  
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PORTAL TRIAD 
Branches of portal vein, hepatic artery and the biliary ducts bound 
together in the perivascular fibrous capsule to form portal triad.  
Hepatocytes are arranged in plates joined with tight junctions  and the  
apical membrane forms the biliary canaliculi. Hepatocytes are segregated 
from the blood-filled sinusoids by fenestrated endothelial cells without a 
basement membrane, and by a loose connective tissue layer known as the 
space of Disse. 
HEPATIC STELLATE CELLS 
These are Star shaped cells that reside in the space of Disse. It 
helps to Store lipids particularly vitamin A. 
Inflammatory cytokines cause activation, which involves the loss 
of stores of vitamin A and a dramatic upregulation in the production of 
extracellular matrix materials, such as collagen. When collagen is 
deposited in the space of Disse it  impairs hepatic function.  
KUPFFER CELLS 
Kupffer cells belongs to macrophage lineage. The sinusoids are lined 
by kupffer cells which clear the cellular debris and other particulate 
material and to some extent bacteria that enters the portal triad. 
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 They express cell-surface receptors for altered proteins. Fc 
immunoglobulin receptors used to internalize foreign proteins or micro-
organisms that have been coated with host antibodies.  
BILIARY SYSTEM 
Gallbladder is a biliary reservoir that lies against the inferior 
surface of segments IV and V of the liver, usually making an impression 
against it. A peritoneal layer covers most of the gallbladder except for the 
portion adherent to the liver. The size is variable, but usually about 10 cm 
long and 3 to 5 cm wide. Gallbladder is composed of a fundus, body, 
infundibulum, and neck . Ultimately empties into the cystic duct  
BIOCHEMICAL FUNCTIONS OF LIVER 
1. Storage fuction-  stores  protein , vitamins, glycogen  and folic 
acid. 
2. Synthesis of plasma proteins , glycogen , phospholipids , bile acids 
and heparin . 
3. Secretory function-secretes  bile acids and bile pigments into the 
bile. 
4. Metabolic function-metabolism of  protein, carbhohydrate  and fat. 
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5. Excretory function-excretion of   hormones, cholesterol, heavy 
metals and bile pigments. 
6. Drugs detoxification. 
7. Production of WBC and RBC during fetal life. 
8. Defence mechanism carried out by kupffer cells. 
PRODUCTION AND METABOLISM OF BILIRUBIN: 
SOURCE OF BILIRUBIN: 
 Mainly 80% is from senescent RBC and about 15 -20 % from 
ineffective erythropoiesis . 
Metabolism of haem containing protein can be divide into three phases:  
(i) Hepatic uptake 
(ii) Conjugation 
(iii) Excretion into bile (rate limiting step) 
UPTAKE:  
 Albumin bound unconjugated bilirubin  enters liver and the 
complex dissociates. Non-polar bilirubin enters the hepatocyte by 
diffusion . It binds to cytoplasmic anion binding protein  ligandin 
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glutathione-s-transferase and prevents  efflux of  bilirubin back into 
plasma. 
CONJUGATION: 
 Unconjugated bilirubin  gets conjugated with glucuronic acid 
forming water soluble bilirubin glucoranide ,catalysed by glucuronyl 
transferase. 
 Conjugation occurs in endoplasmic reticulam.  
EXCRETION: 
 Water soluble conjugated bilirubin is excreted into the biliary 
canaliculi by the hepatocytes . In gut it is converted to stercobilinogen by 
bacteria and Oxidized to stercobilin which is colored. Excreted in feces. 
Some stercobilin may be re-adsorbed by the gut and re-excreted by either 
the liver or kidney  
 
 
 
 
12 
 
 
Fig. 3. Bilirubin Metabolism 
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Fig. 4. Bilirubin Metabolism  
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Causes of  Unconjugated hyperbilirubinaemia: 
1. Increased bilirubin formation  e.g., Haemolysis ,  Ineffective  
erythropoiesis ,  Blood transfusion and  Haematoma. 
2. Decreased bilirubin uptake by hepatocyte  e.g.,Drugs like Rifampicin, 
Gilbert’s syndrome 
3. Deficit in conjugation -Gilbert’s syndrome ,  Crigler Najjar syndrome 
,  Drugs 
Diseases  of  Unconjugated hyperbilirubinaemia: 
1) Dubin-Johnson syndrome, Rotor’s syndrome 
2) Hepatocellular dysfunction 
3) Hepatic disorder with prominent cholestasis 
4) Biliary duct obstruction.ionon 
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PREHEPATIC JAUNDICE 
Prehepatic jaundice results from excessive RBC lysis as in haemolytic 
anaemia . Unconjugated bilirubin level is increased. 
 
Fig. 5. Prehepatic Jaundice 
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HEPATIC JAUNDICE 
 As a result of liver dysfunction there is impairment of uptake , 
conjugation and secretion of bilirubin , hence both direct and indirect 
bilirubin level increases. 
 
Fig. 6 Intrahepatic Jaundice 
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POSTHEPATIC JAUNDICE 
When there is obstruction to biliary tree , the  conjugated biliribin 
level gets elevated. 
 
Fig. 7. Posthepatic Jaundice 
 
 
 
18 
 
Causes Jaundice 
Bilirubin in 
serum 
Bilirubin 
in urine 
Ubg in 
urine 
Ubg in 
faeces 
Prehepatic Haemolytic  ↑ indirect No ↑ ↑ 
Hepatic  Hepatic  ↑Both direct 
and indirect 
Yes ↓ ↓ 
Posthepatic Obstructive ↑Direct  Yes No No 
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REVIEW OF LITERATURE 
 
In pregnancy the liver exhibits a range of altered functions 
including changes in blood flow to liver, cholesterol synthesis and 
secretion, motility of gall bladder is reduced.  
Abnormal liver function test occur is 3%-5% of all pregnancies.  
There will be rise in serum bilirubin level during pregnancy due to 
delayed excretion. A  rise in alkaline phosphates, LDH and transaminases 
also noted. The rise in alkaline phosphatases is due to the contribution 
from placenta.  
Hematocrit, serum urea, uric acid, albumin and total protein values 
falls,a rise is noted in cholesterol and triglyceride levels.  
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LIVER FUNCTION TEST & PREGNANCY 
 Non-Pregnant Pregnant 
Bilirubin  2-17 µmol/L No Change  
Transaminases 7-40 IU/L No Change  
        Gamma glutamyl 
transferase 
<30 IU/L No Change  
Sr.Alkaline 
phosphatase 
30-130 IU/L Progressive rise after 5
th
 week 
due to placental and  skeletal 
component 
Prothrombin time 8-14 sec No Change  
Total proteins 6.5-8mg/dl decreases by 1mg/dl by 16
th
 -
20
th
 week 
Albumin  3.5-5.5mg\dl decreases by 1mg/dl mostly 
in first trimester 
Globulin 3-5 mg/dl Rises progressively to term 
Fibrinogen 2-4 g/L Rises progressively to term 
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CLASSIFICATION OF JAUNDICE IN PREGNANCY 
I) Diseases unique to pregnancy  
1)  Hyperemesis gravidarum 
2)  Intrahepatic cholestasis of pregnancy 
3)  Pre-eclampsia 
4)  HELLP Syndrome  
5)  Acute fatty liver of pregnancy  
II) Co-incidental to pregnancy  
1)  Viral Hepatitis  
2)  Gall stones 
3)  Drugs 
4)  Sepsis  
III) Underlying chronic liver disease 
1)  Chronic hepatitis B & C 
2)  Autoimmune Hepatitis 
3)  Cirrhosis of liver 
4)  Wilson disease 
  
 
 
22 
 
HYPEREMESIS GRAVIDARUM 
Intractable severe vomiting in the first trimester of pregnancy 
necessitating intravenous rehydration. Occurs in 0.3% of all pregnancies.  
Etiology is hormonal, immunological and psychological factors. 
Risk factors include hyperthyroidism, psychiatric illness, molar 
pregnancy, pre existing diabetes and  multiple pregnancies
1
. 
 
Liver dysfunction occur in 50% of patients with elevation in amino 
transferase upto 20 fold.  
The balance of liver enzymes will return to normal when 
dehydration and malnutrition are corrected.  
Both steroids and ondansetron are effective for treatment
2
.  
Rare complications include wernicke's encephalopathy, 
oesophageal  rupture, central pontine  myelinolysis, retinal haemorrhage
2
. 
INTRAHEPATIC CHOLESTATIS OF PREGNANCY  
Second cause next to viral hepatitis for jaundice in pregnant 
woman. Occurs in second half of pregnancy with pruritis, elevated bile 
acid levels, disappears after delivery and recurrence is common.  
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Fig. 8. Histopathology of Cholestasis Of Liver 
 IHCP is due to abnormal biliary transport across canalicular 
membrane the etiology for which is heterogenous with hormonal, genetic 
and exogenous factors exerting influence on hepatocyte or canalicular 
membrane of different individual.  
Sex hormones have known cholestatic effects  and abnormal 
progesterone metabolism is found in IHCP.  
Atleast 10 different MDR3 mutations have been identified in ICP  
One report has shown that certain  MDR3 gene variants (ABCB4) 
is associated with severe form of IHCP
3
.  
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Fetal complications such as sudden fetal death and premature 
labour are due to placental insufficiency and elevated fetal levels of bile 
acids
4
.  
High maternal levels of bile acids correlate with fetal morbidity 
and mortality
6
. 
CLINICAL FEATURES AND DIAGNOSIS 
Pruritis starts around 25-32 weeks of gestation. It is worse at night 
and affects all parts of body. Jaundice occurs in 10-25%  about 2-4 weeks 
after pruritis ,mild elevation to 10-20 fold elevation of amino transferase 
seen. Bilirubin is usually less than 5 mg/dl. 
The most specific and sensitive marker of IHCP is serum bile acid. 
Levels of greater than 10µmol/l  and sometimes  upto 100 fold elevation 
is seen.  
MANAGEMENT  
• UDCA 10-15 mg/kg is treatment of choice 
7
 
• Dexamethasone 12 mg/day for 7 days.  
•  S.adenosyl methionine is less effective than UDCA but has an 
additive effect
8
.  
 
 
25 
 
 The main risk of IHCP is to the fetus. A swedish population study 
of more than 45,000 pregnancies with 693 cases of IHCP showed a 
positive correlation between maternal bile acid levels and premature 
delivery asphyxial events and meconium staining
6
. 
A recent large finnish population study showed that patients who 
have had IHCP developed cholecystitis, gall stones, non alcoholic 
pancreatitis, Hepatitis C and non alcoholic cirrhosis. 
ACUTE FATTY LIVER OF  PREGNANCY 
It is a sudden catastrophic illness occurring most exclusively in 
third trimester, where microvesicular fatty infiltration results in 
encephalopathy and hepatic failure
9
. Incidence is approximately 1 in 
14,000 pregnancies. Women with this condition give birth to male births 
commonly
10,11
.  
ETIOLOGY :  
Etiology of acute fatty liver of pregnancy involves abnormalities in 
intra mitochondrial fatty acid oxidation
12
. Beta-oxidation of fatty acid in 
hepatic mitochondria requires several enzymes. 
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Mitochondrial trifunctional protein and its alpha subunit long chain 
3-hydroxyacyl – CoA dehydrogenase (LCHAD) are 2 main enzymes and 
the genetic mutation in LCHAD is closely associated with AFLP. 
LCHAD deficiency has been identified in about 20% of babies of 
mothers with AFLP.  Maternal heterozygosity for LCHAD deficiency 
decreases the maternal capacity to oxidize long chain fatty acids in liver 
and placenta leading to accumulation of hepatotoxic LCHAD metabolites 
in maternal circulation
13
. 
CLINICAL FEATURES AND DIAGNOSIS  
Burroughs et al., and others reported that women with AFLP have 
an increased frequently of Pre-eclampsia signs and are more likely in 
primigravida (50%) and have 10-15% increased incidence in twin 
pregnancies
14
.  
The presentation varies from asymptomatic to fulminant hepatic 
failure. Typical features would be 1 to 2 weeks of anorexia, headache, 
nausea, malaise, right upper quadrant pain with signs of jaundice, 
hypertension, ascites, small liver and hepatic encephalopathy 50% 
patients with AFLP have pre eclampsia and there is some overlap with 
HELLP syndrome
15
.  
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Laboratorical features would be elevated bilirubin levels, amino 
transferase vary from near normal to 1000, usually about 300 to 500, 
normocytic normochromic anemia, high WBC count, normal to low 
platelets, coagulopathy with or without DIC, renal dysfunction, 
hypoglycemia.  
Plasma urea, uric acid and creatinine levels are usually elevated. 
Uric acid levels may increase days before symptoms of AFLP become 
manifest
16
, therefore serve as a pointer  towards early diagnosis
17
.  
AFLP diagnosed presumptively by clinical and laboratorical 
features, a definitive diagnosis is histological Microvesicular fatty 
infiltration in zone 3 and portal inflammation with cholestasis seen.  
Differential diagnosis include fulminant viral hepatitis and HELLP 
syndrome.  
MANAGEMENT  
Immediate termination of pregnancy and intensive supportive care 
is essential for both maternal and fetal survival. 
INR of 1.5 and platelet count of >50,000 should be maintained, 
prophylactic antibiotic are recommended to prevent uterine infection. 
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With advanced supportive management the maternal mortality now 
is 7%-18% and fetal mortality 9%-23% 
Infections and bleeding complications remain the most life 
threatening.  
RECURRENCE AND SCREENING  
   Women who are carriers of LCHAD mutation have an increased risk of 
recurrence of AFLP in 20%-70% of pregnancies. Babies of mothers with 
AFLP should be screened for FAO defects as early diagnosis and 
appropriate management will reduce morbidity and mortality in these 
babies
18,19
.  
HYPERTENSION ASSOCIATED LIVER DYSFUNCTION OF 
PREGNANCY  
Pre eclampsia : 
Pre-eclampsia comprises a triad of Hypertension, edema and 
proteinuria, arises in third trimester and occurs in 5-10% of pregnancies.  
With mild hypertension, 24% of patients have abnormal amino 
transferase levels, increasing to more than 80% in those with severe 
hypertension
20
. 
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Liver involvement although infrequent always indicate severe pre 
eclampsia with significant morbidity and mortality.  
It is the commonest cause of hepatic tenderness and liver 
dysfunction in pregnancy.  
Early delivery is the key for treatment as hepatic complications 
accounts for 16% deaths of pre eclampsia, usually by hepatic rupture
21
.  
Periportal haemorrhage occurs in severe cases of eclampsia and in 
very severe cases they may form hematoma which ruptures 
22,23 
liver 
infarcts secondary to hepatic arterial thrombosis, which is associated with 
very high amino transferase levels.  
The results of liver function test follow a standard pattern after 
delivery. 
- Amino transferase level decrease after 24 h 
- Bilirubin levels falls within 72 hrs.  
- Alkaline phosphatase and GGT rise on day 5 or 6, peak on day 
10 and return to normal within 8 weeks
24
.  
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HELLP Syndrome  
 Severe pre eclampsia in 2%-12% of cases will be complicated by 
Hemolysis (H), Elevated liver enzymes (EL) and low platelet count (LP) 
the HELLP syndrome. 
Diagnostic criteria for HELLP syndrome. 
Hemolysis              Elevated liver tests   Low platelets  
Abnormal blood smear     AST > 70/L                     < 1,50,000 
LDH> 600 U/L   
Increased Indirect Bilirubin 
HELLP syndrome may be subdivided, based on platelet count, into 
severe / class 1 (platelets < 50,000) Moderate / Class 2 (50-99,000) and 
Mild / Class 3( 100-1,50,000) 
ETIOLOGY : 
HELLP syndrome is a microangiopathic hemolytic anemia 
associated with vascular endothelial injury leading to platelet 
consumption, resulting in small to diffuse haemorragic areas which 
spread to cause hematomas, capsular tears and intra peritoneal bleeding. 
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 It was found that women heterozygous for factor V Leiden have an 
increased risk of developing HELLP syndrome
25
 , while placental CD 95 
ligand has been shown to act systematically to cause liver damage in 
patients with  HELLP syndrome
26
. 
CLINICAL FEATURES AND DIAGNOSIS  
Upper abdominal pain and tenderness, nausea, vomiting, malaise, 
head ache, edema and weight gain, Hypertension and proteinuria.  
Jaundice is uncommon (5%) 
Common in older, white, multiparous ladies. Diagnosis is made on 
3 laboratorical criteria (1) Hemolysis (2) Elevated aminotransferase (3) 
thrombocytopenia. 
There is some overlap between AFLP and HELLP syndrome. HUS 
& TTP also have similar presentations. 
MANAGEMENT  
Majority of patients recover soon after delivery, only life 
threatening complications are taken as indication for specific therapy with 
plasmapheresis, plasma volume expansion, anti thrombotic agents, 
steroids, fresh frozen plasma dialysis.  
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Perinatal mortality is 11% due to prematurity, dysmaturity due to 
placental insufficiency.  
RECURRENCE : 
 Pre eclampsia, recurrent HELLP, pre maturity, IUGR, abruption 
placentae recur in subsequent pregnancies in patients with HELLP 
syndrome.   
VIRAL HEPATITIS IN PREGNANCY 
Viral hepatitis is caused mostly by 5 hepatotrophic viruses, namely 
Hepatitis A, B, C, D, E.  
Cytomegalovirus, Ebstein – Barr virus, Herpes simplex virus are 
rare causes of actue hepatitis in pregnancy.  
Acute viral Hepatitis is characterized by marked increase in serum 
levels of ALT and AST due to liver cell necrosis. The serum level of 
alkaline phosphatase remains normal or mildly elevated, except for 
marked rise in infection due to hepatitis A virus or hepatitis E virus.  
Hepatitis A virus  
Non enveloped 27 nm RNA virus, transmitted through faeco oral 
contamination. 
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Poor hygiene, poor sanitation and intimate personal or sexual 
contact facilitate transmission. 
In developing countries, more than 90% population is exposed to 
HAV infection in childhood and possess anti-HAV antibody  
Acute hepatitis A is a self limiting disease and the prognosis in 
pregnancy is the same as non pregnant patient.  
Prevention is by avoidance of exposure and vaccination.  
Hepatitis B Virus  
 Double standard DNA virus.  
Genome of HBV has four open reading frames that encode four 
major proteins surface protein (HBSAG), Core proteins (HBC Ag & HBE 
Ag), DNA polymerase and X protein.  
Once a person gets infected with HBV, first viral marker detected 
is serum HbSAg followed by elevation of serum transaminases and 
clinical symptoms.  
HbSAg becomes undetectable 1 or 2 months after the onset of 
jaundice and rarely persists after 6 months. Afterwhich, anti HbSAg 
becomes detectable in serum.  
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HBC Ag confined to liver cells and therefore not detectable in 
serum.  
Anti HBC is readily demonstrable in serum 1 or 2 weeks after 
appearance of HbSAg.  
Recent and Remote infection distinguished by Immunoglobulin 
class of anti HBC. IgM anti-HBC predominates in first 6 months whereas 
beyond 6 months Ig G – anti HBC predominates.  
 
Fig. 9. Histopathology of Acute Viral Hepatitis 
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Hbe Ag becomes detectable in serum concurrent with or short after 
appearance of HbSAg.  
Earlier the age of acquisition of HBV infection, higher the 
propensity for chronic disease. The natural course of HBV in chronic 
carriers varies from an inactive state to recurrent acute exacerbations. 
Chronic hepatitis, cirrhosis and hepatocellular carcinoma may develop 
after a prolonged period.  
When an asymptomatic pregnant woman is found to be hepatitis B 
surface antigen positive at the time of her first antenatal visit, we have to 
differentiate between a chronic carrier and an acute infection.  
No evidence proves that hepatitis B infection is more common 
during pregnancy. As HBe Ag is a marker of active replication. If the 
mother is positive for both HBs Ag and HBe Ag, the risk of transmission 
to child is 70-90%, whereas the risk of transmission is 10-20% if mother 
positive only for HBs Ag. 
Infants of HBsAg positive mothers should receive Hepatitis B 
immunoglobulin (HBIG) in addition to the HBV vaccine. HBIG when 
given to newborn in first 24 hours of delivery infection is prevented in 
80-85% 
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HEPATITIS C VIRUS  
Enveloped single stranded RNA virus. Only 10-15% of HCV 
infected patients develop hepatitis and the rest remain asymptomatic. 50-
85% become chronic carriers. Process of liver damage is slow and takes 
about 30-40 years before cirrhosis and hepato cellular carcinoma occur.  
 There may be intermittent or persistent risk in serum transaminases 
accompanied by histological changes in the liver that range from a mild 
to severe chronic active hepatitis and cirrhosis.  
Mode of transmission is via blood and blood products, sexual 
contact and sharing of needles among intravenous drug abusers.  
Maternal – infant transmission has become an important mode of 
spread of infection.  
Co-infection with HIV increases the risk for HCV transmission 
significantly.   
Type of delivery does not seem to influence the rate of mother to 
infant transmission.  
Routine screening for her in pregnancy not recommended, 
However, screening of high risk groups, such as HIV patients, previous or 
current injectable drug abuse, those who received blood transfusions 
before becomes mandatory. 
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Hepatitis D Virus  
Single stranded circular RNA virus, which depends on the presence 
of HBV for its replication. Co-infection with HBV and HDV causes more 
severe disease with higher chronicity rate.  
Hepatitis E Virus  
Non-enveloped, single stranded RNA virus.  
Diagnosis of acute hepatitis E infection is made by demonstration 
of IgM anti HEV antibodies in the serum.  
Pregnant women, particularly those in second and third trimesters, 
are more frequently affected during Hepatitis E outbreaks.  
Disease is more severe when infection occurs in third trimester 
with mortality rates between 15% to 25% 
HEV infection adversely affects fetal outcome, with increased 
incidence of abortions, still births and neonatal deaths.  
Administration of immunoglobulins to pregnant women during on 
outbreak of HEV has been reported to reduce the risk of infection.  
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Gall Stones :  
Cholesterol secretion increases in the second and third trimester 
compared to bile acids and phospholipids, leading to supersaturated bile, 
in addition, fasting and post prandial gall bladder volumes are greater 
with reduced rate and volume of emptying.  
Upto 10% of patients develops stone on sludge over the course of 
one pregnancy with obesity and serum leptin being risk factors
28
.  
Commonest clinical presentation is Biliary colic (5% jaundice in 
pregnancy), gall stone pancreatitis and least commonly acute 
cholecystitis.  
Biliary colic will recur in 50% of pregnant patients. Before 
delivery, symptomatic patients should undergo laparoscopic 
cholecystectomy in the second trimester with better pregnancy outcome 
compared with medical therapy
29,30
.  
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UNDERLYING CHRONIC LIVER DISEASES 
CIRRHOSIS AND PORTAL HYPERTENSION 
Most patients with advanced cirrhosis are amenorrhic and infertile. 
Successful pregnancy may be completed in those with well compensated 
disease and only mild portal hypertension. Increased maternal and fetal 
problems can be expected in about 50% cases with increased fetal loss 
and maternal risks of hepatic decompensation, jaundice, 
thrombocytopenia, rupture of splenic aneurysm, variceal bleeding (20-
25%). Patients with oesophageal varices should be considered for 
endoscopic therapy, shunt surgery or even liver transplantation before 
pregnancy. 
 
Fig. 10 Caput Medussae 
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Fig.  11 Histopathology of Cirrhosis Of Liver 
 Vaginal deliveries with assisted second stage of labour can be done 
in mild cases. But with large varices, avoidance of labour by cesarean 
section is recommended to avoid increase in portal pressure and risk of 
variceal bleeding.  
Correction of coagulopathy and prophylactic antibiotics given to 
reduce the incidence of postpartum haemorrhage and bacterial infection.   
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OTHER INFECTIONS 
Malaria : 
 Malarial infection can be endemic or sporadic  caused by 
Plasmodium species. The incubation period varies from 8-25 days. The  
anopheles mosquito is the vector. Symptoms  are fever and flu like 
symptoms including malaise, vomiting and headache which may occur in 
intervals. Symptoms are less severe in immune patients. Malaria may be 
associated with jaundice and anaemia. Jaundice is due to hemolysis and 
hepatitis. Liver and spleen enlarge and become tender. 
Effect on pregnancy : 
 Pregnant women have an increased incidence of infection 
.Parasitaemia may be great. Severe anaemia in pregnancy is a major 
obstetric problem in malaria endemic area. Haemolytic anemia which can 
cause jaundice may be severe in pregnancy and hepatorenal syndrome is 
often the cause of death. Malaria may present as puerperal pyrexia 
following delivery in women with low immunity.Most important 
complication is Postpartum haemorrhage. Malaria can infect placenta 
leading to maternal anaemia, spontaneous abortion, intrauterine death, 
stillbirth and low birth weight. Intrauterine death is  caused by massive 
infection of the placenta and persistent high fever.In non-immune 
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mothers  malarial parasites can cross placenta  leading to congenital 
malaria. In endemic areas WHO recommends malarial chemoprophylaxis 
throughout pregnancy. It is given as weekly prophylaxis with chloroquine 
in a dose of 300mg/wk. 
LEPTOSPIROSIS : 
 About 5-10% of patients with leptospirosis will have hepatic and 
renal involvement. Transmitted by direct contact with urine, tissue or 
blood of an infected animal. Entry is through abrasions in skin or through 
intact mucous membrane. Incubation period is 2-20 days.  90%of patients 
have relatively mild and anicteric form of leptospirosis. Severe 
leptospirosis may present as renal dysfunction, jaundice and 
haemorrhagic diathesis referred as Weil’s syndrome. There is marked 
elevation of serum billirubin and alkaline phosphatase with moderate 
elevation of aminotransferases in patients with liver involvement. 
Diagnosis is based on either isolation of the organism or a rise in 
antibody titre in Microscopic slide agglutination test (MAT).  
Effect on pregnancy : 
 Perinatal mortality is high in leptospirosis. 30% of pregnancies 
ended in abortion or preterm death. Vertical transmission is rare. Drug of 
choice is Penicillin G in a dose of 1.5million units IV qid. Other 
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alternative are erythromycin and ampicillin. Doxycycline is 
contraindicated in pregnancy. 
Typhoid : 
 Enteric fever is endemic in most developing regions especially in 
India. Transmission is by ingestion of contaminated water or food. 
Incubation period is 3-21 days. The  prominent symptom is prolonged 
fever. It is seen in 75% of cases. Gastrointestinal symptoms are quite 
variable. Only 20-40% of patients have abdominal pain. Hepatic 
dysfunction, though less common can occur in patients with typhoid 
fever. Moderate elevation of Liver function tests  might be present. 
Effects on  Pregnancy : 
The acute infection in pregnant women run a similar course to those in 
non pregnant women. Vertical transmission  has been recorded. Around 
3% of patients with severe form of typhoid fever may go for spontaneous 
abortions and preterm labor. But effective antibiotic treatment has made 
this outcome less common. Chloramphenicol is the drug of choice  but 
other options are ciprofloxacin,  azithromycin and ceftriaxone. 
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Herpes Viruses : 
All members of herpes group – Herpes simplex, Epstein barrvirus, 
cytomegalo virus and varicella  can cause hepatitis. More than half are 
associated with immunosuppression. Jaundice is not invariable and 
mucocutaneous stigmata may be absent. Herpes simplex hepatitis carries 
a grave prognosis. Mortality exceeds 90% even with treatment. Herpes 
simplex  type II is most common in 3rd trimester. Symptoms are three 
times more common in pregnancy. The virus can cross placenta but it has 
no relation with congenital malformation. HSV II acquired at birth from 
cervical and vaginal contamination can lead to disseminated infection in 
babies with 90% mortality. Pregnancy is a high risk factor and has been 
associated with a high maternal and fetal mortality rate. Acyclovir 
appears to improve the outcome. 
Congenital non-haemolytic Hyperbilirubinemia : 
 GILBERT’SDISEASE: 
 Gilberts disease presents as mild fluctuating jaundice which may 
only be noticed when the patient is tired, dehydrated or calorie depleted. 
As all of these may occur during normal pregnancy, diagnosis of gilbert’s 
disease may be made for the first time during pregnancy. Serum billirubin 
is elevated, but liver enzymes are normal, there is no sign of any systemic 
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disease and no symptoms other than jaundice. Maternal and perinatal 
outcome are not affected by the disease. It is relatively common in 
Western Societies with the prevalence rate of 1-2%. There are no 
significant risks with the diagnosis but precipitating factors should be 
minimized. 
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MATERIALS AND METHODS 
Forty Six  women with jaundice complicating pregnancy admitted and 
treated at Government Coimbatore Medical College  Hospital, 
Coimbatore from August 2013 to August 2014 were studied. 
• A detailed history including patient’s age, socioeconomic status, 
booking, parity and details of menstrual history to arrive at the 
expected date of delivery was obtained. 
• Patients were enquired in detail about their complaints and duration 
like nausea, vomiting, pruritus, anorexia, yellow coloured urine, 
pale stools, edema legs, bleeding tendency, joint pain, fever and 
others. 
• Past history of jaundice especially in previous pregnancy and  
history of  blood transfusion were elicited. 
•  Systemic and obstetric examinations were carried out.  
• Investigations included liver function tests, serum billirubin, SGOT, 
SGPT, alkaline phosphatase, Viral markers, prothrombin time (PT), 
partial thromboplastin time (PTT), bleeding time (BT), clotting time 
(CT), platelet count and ultrasound abdomen were carried out as 
and when required.        
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• HIV screening was done in all patients. 
• Medical gastroenterologist opinion was obtained for all cases. 
• Labour was closely monitored. Jaundice per se was not an 
indication for cesarean section. Vaginal delivery with close 
monitoring was preferred and cesarean sections were done only for 
obstetric indication. After cross matching fresh blood, fresh frozen 
plasma was kept ready as alteration in coagulation profile was 
expected in jaundice complicating pregnancy. 
• Atonicity was managed with oxytocin drip , injection methergin and 
injection 15 methyl PGF2α. 
• Patient were kept in the labour ward for close observation. Clotting 
time was repeated hourly if it was prolonged till it becomes normal. 
• Soon after delivery all babies were assessed by paediatrician. Alive 
or dead , sex , gestational age at birth , weight , apgar score and 
presence or absence of any congenital anomalies were looked for 
and noted. As per paediatrician opinion sick babies were admitted in 
preterm ward for intensive care.                                    
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• The maternal outcome was noted in terms of the mode of 
termination of pregnancy, maternal complications and maternal 
mortality.The relation of maternal morbidity and mortality to the 
admission serum bilirubin level was analysed. 
• To identify the various etiologies and distribution of jaundice with 
reference to age , parity and trimesters. 
• Fetal outcome was assessed by perinatal morbidity and mortality 
• Study design: Prospective cohort study 
• Study Population : 46 patients  
• Inclusion Criteria : All jaundiced antenatal mothers attending 
Obstetrics and Gynaecology Department in Coimbatore Medical 
College Hospital. 
• Exclusion Criteria : Patients on Hepatotoxic Drugs, Jaundice due to 
Sepsis. 
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OBSERVATIONS AND RESULT 
The incidence of jaundice in India varies from 0.4-0.9 per 1000 
deliveries. A prospective study of all antenatal patients admitted to 
Coimbatore medical college with jaundice was evaluated from august 
2013- august 2014. Total number of admissions during this period was 
12,286. According to this study the incidence of jaundice is 3/1000 
deliveries. 
Singh et al reported a jaundice incidence of 1.03/1000.kamala 
jayaram and rama devi 2 reported an incidence of 0.4/1000. 
AGE GROUP: 
           Of the 46 women studied ,45.7% were in the age group of 21-25 
years(TABLE 1) 
PARITY AND GESTATIONAL AGE: 
             About 41.3% women of 46 were primi and 30.4% second 
gravida. The incidence is more common in third trimester 93.5 
%(TABLE 2 & 3) 
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ETIOLOGY  OF JAUNDICE:  
      Of the 46 women, 25 had viral hepatitis (54.3%), 12 had HELLP 
syndrome(26.1%),3 had acute fatty liver of pregnancy (6.5%), 3 had intra 
hepatic cholestasis of pregnancy (6.5%),cirrhosis (6.5%) (TABLE 7 ). 
COMPLICATIONS : 
 Of the 46 women , 33 recovered without major complications 
(71.7%), 5 developed DIC (10.9%), 3 had Atonic PPH (6.5%), out of 
which 2 expired, 1 developed hepatic encephalopathy (2.2%), 1 had ARF 
(2.2%), 1 splenic rupture (2.2%),1 variceal bleed(2.2%), 1 vulval 
hematoma (2.2%). (TABLE  8)       
MATERNAL OUTCOME: 
     Among the 46 women studied, 43 delivered and 3 were undelivered, 
of the 3 undelivered 2 expired, out of the 43 delivered ,23 was labour 
natural (50%),19 had LSCS (12.5%), 1 was VBAC (12.5%). Of the 8 
deaths  3 were due to DIC (37.5%),2 due to Atonic PPH (25%),1 
developed hepatic encephalopathy (12.5%),1 of splenic rupture (12.5%), 
1 of variceal bleed (12.5%).(TABLE 9) 
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FETAL OUTCOME: 
 Of the 43 delivered, 37 was live birth (86%), 6 dead born (14%). 
Out of 37 , 28 were term babies (75.7%), 9 were preterm (24.3%). 20 
male babies (46.5%),23 female babies (53.5%).44.2% of babies weighed 
<2.5 kg, 51.2% weighed between 2.5-3.5 kg, only 4.7% weighed more 
than 3.5 kg.(TABLE 12,13,14,15). 
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ANALYSIS  
 
TABLE 1 
AGE DISTRIBUTION  
 
AGE FREQUENCY PERCENTAGE 
<20 5 10.9 
21-25 21 45.7 
26-30 14 30.4 
31-35 6 13 
TOTAL 46 100 
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TABLE 2 
TRIMESTER DISTRIBUTION 
 
S.NO TRIMESTER FREQUENCY PERCENTAGE 
1 I 1 2.2 
2 II 2 4.3 
3 III 41 93.5 
 TOTAL 44 100 
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TABLE 3 
PARITY DISTRIBUTION  
 
S.NO PARITY FREQUENCY PERCENTAGE 
1 Primi 19 41.3 
2 G2 14 30.4 
3 G3 6 13.0 
4 G4 - 0.0 
5 G5 3 6.5 
6 G6 1 2.2 
7 G9 1 2.2 
8 P1L1 2 4.3 
 TOTAL 46 100 
 
Out of the total 46 woman, 41.3% were primi and 30.4% were 
second gravida. 
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 TABLE 4  
PREGNANCY OUTCOME  
 
S.NO OUTCOME TOTAL PERCENTAGE 
1 UNDELIVERED 3 6.5 
2 DELIVERED 43 93.5 
 TOTAL 46 100 
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TABLE 5 
 MODE OF DELIVERY  
 
S.NO MODE OF DELIVERY FREQUENCY PERCENTAGE 
1 LABOUR NATURALE 23 50 
2 LSCS 19 41.3 
3 UNDELIVERED 3 6.5 
4 VBAC 1 2.2 
 TOTAL 46 100 
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MODE OF DELIVERY  
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TABLE 6 
LEVEL OF INITIAL BILIRUBIN 
 
S.NO INITIAL BILIRUBIN TOTAL  PERCENTAGE 
1 <5 25 54.3 
2 5-10 10 21.7 
3 10-15 5 10.9 
4 >15 6 13 
 
 
 of the 46 women, 25 that is 54.3% had a initial bilirubin level of <5 
, and only 6 women had bilirubin levels >15 , among them 3 expired 
giving that 50% of jaundiced patients with bilirubin levels more than 15 
had mortality. 
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TABLE 7 
ETIOLOGY OF JAUNDICE  
 
S.NO ETIOLOGY TOTAL PERCENTAGE 
1 VIRAL 25 54.3 
2 HELLP 12 26.1 
3 AFLP 3 6.5 
4 IHCP 3 6.5 
5 CIRRHOSIS 3 6.5 
6 TOTAL 46 100 
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CHART 7 
ETIOLOGY OF JAUNDICE  
 
ied, 25 had viral hepatitis (54.3%), 1
AFLP,3 cholestatic jaundice and 3 
 
 
12
3 3
HELLP AFLP IHCP
 
2 had HELLP 
cirrhosis with 
3
CIRRHOSIS
 
 
66 
 
TABLE 8 
MATERNAL COMPLICATIONS  
 
S.NO COMPLICATIONS TOTAL  PERCENTAGE 
1 DIC 5 10.9 
2 ATONIC PPH 3 6.5 
3 HEPATIC ENCEPHALOPATHY 1 2.2 
4 PRERENAL ARF 1 2.2 
5 SPLENIC RUPTURE 1 2.2 
6 VARICEAL BLEED 1 2.2 
7 VULVAL HEMATOMA 1 2.2 
8 NIL 33 71.7 
 TOTAL 46 100 
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TABLE 9 
CAUSE OF DEATH 
 
S.NO CAUSE OF DEATH TOTAL PERCENTAGE 
1 DIC 3 37.5 
2 ATONIC PPH 2 25 
3 HEPATIC 
ENCEPHALOPATHY 
1 12.5 
4 SPLENIC RUPTURE 1 12.5 
5 VARICEAL BLEED 1 12.5 
 TOTAL 8 100 
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TABLE 10 
BLOOD TRANSFUSIONS 
 
S.NO TRANSFUSIONS TOTAL PERCENTAGE 
1 <5 8 38.1 
2 5-10 9 42.9 
3 11-15 3 14.3 
4 16-20 - 0 
5 >20 1 4.8 
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BLOOD TRANSFUSIONS 
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TABLE 11 
VIRAL ETIOLOGY 
 
S.NO ETIOLOGY TOTAL PERCENTAGE 
1 HBV 21 84 
2 HEV 4 16 
3 HCV -  
 TOTAL 25 100 
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VIRAL ETIOLOGY 
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TABLE 12 
FETAL OUTCOME  
 
S.NO OUTCOME TOTAL PERCENTAGE 
1 LIVE BIRTH 37 86 
2 DEAD BORN 6 14 
3 ABORTUS -  
 TOTAL 43 100 
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TABLE 13 
MATURITY OF THE BABY 
 
S.NO MATURITY TOTAL  PERCENTAGE 
1 TERM 28 75.7 
2 PRETERM 9 24.3 
 TOTAL 37 100 
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MATURITY OF THE BABY 
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TABLE 14 
SEX OF THE BABY  
 
S.NO SEX TOTAL PERCENTAGE 
1 MALE 20 46.5 
2 FEMALE 23 53.5 
 TOTAL 43 100 
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SEX OF THE BABY  
 
en delivered, 20(46.5%) were male,
 
 
and 23(53.5%) 
MALE
47%
 
 
80 
 
TABLE 15 
BIRTH WEIGHT OF THE BABY  
 
S.NO BIRTH WT TOTAL PERCENTAGE 
1 <2.5 19 44.2 
2 2.5-3.5 22 51.2 
3 >3.5 2 4.7 
 TOTAL 43 100 
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TABLE 16 
RELATION OF MATERNAL AGE TO  
MATERNAL MORTALITY 
S.No Age group No. of cases 
Maternal 
mortality 
% of mortality 
in relation to age 
1 <20 5  0 
2 21-25 21 4 50 
3 26-30 14 3 37.5 
4 31-35 6 1 12.5 
 TOTAL 46 8 100 
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TABLE 17 
GRAVIDITY IN RELATION TO MATERNAL MORTALITY  
 
S.NO GRAVIDITY 
NO.OF 
CASES 
MATERNAL 
MORTALITY 
%OF 
MORTALITY 
1 PRIMI 19 5 62.5 
2 G2 14 1 12.5 
3 G3 6 1 12.5 
4 G4 - - - 
5 G5 3 1 12.5 
6 G6 1 - - 
7 G9 1 - - 
8 P1L1 2 - - 
 TOTAL 46 8 100 
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TABLE 18 
ETIOLOGY IN RELATION TO MATERNAL MORTALITY 
 
S.NO ETIOLOGY 
NO.OF 
CASES 
MATERNAL 
MORTALITY 
% OF 
MORTALITY 
1 VIRAL 25 3 37.5 
2 HELLP 12 2 25 
3 AFLP 3 1 12.5 
4 IHCP 3 - - 
5 CIRRHOSIS 3 2 25 
 TOTAL  46 8 100 
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TABLE 19 
RELATION OF SERUM BILIRUBIN LEVELS TO  
MATERNAL MORTALITY  
 
S.NO 
BILIRUBIN 
LEVELS 
NO.OF 
CASES 
MATERNAL 
MORTALITY 
% OF 
MORTALITY 
1 UPTO 5 25 1 12.5 
2 6-10 10 2 25 
3 11-15 5 2 25 
4 >15 6 3 37.5 
 TOTAL 46 8 100 
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TABLE 20 
RELATION OF MODE OF DELIVERY TO  
MATERNAL MORTALITY  
 
S.NO MODE OF DELIVERY 
NO.OF  
CASES 
MATERNAL 
MORTALITY 
% OF 
MORTALITY 
1 LABOUR NATURALE 23 4 50 
2 LSCS 19 1 12.5 
3 VBAC 1 1 12.5 
4 UNDELIVERED 3 2 25 
 TOTAL 46 8 100 
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DISCUSSION 
 
The incidence of Jaundice among the pregnant women attending 
the Coimbatore Medical College Hospital, Coimbatore from August2013 
to August 2014 is 3 per 1000 population. The incidence in various places 
by various authors is shown in the following table. 
S.No. Author Year 
Incidence per 
1000 population. 
1. Sarkar et al (Calcutta) 1992 2.3 
2. Reddi  Rani   et    al 
(Pondicherry) 
1993 1.17 
3. Devinder Kaur et al (Delhi) 2011 0.92 
 Our hospital incidence correlates with the study of  
sarkar et al, 1992. Our hospital incidence is very high when compared to 
Western countries where it is 1 in 1500 pregnancies (Williams 2010). 
This is because of higher prevalence of malnutrition, poor sanitation and 
low socioeconomic status in our country. 
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ETIOLOGY 
 In the present study viral hepatitis was found to be the commonest 
cause (54.3%) next being HELLP syndrome (26.1%) third in order is 
acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, 
chronic liver disease such as cirrhosis with portal hypertension each 
contributing 6.5%. Patients with viral hepatitis was the major group with 
Jaundice in pregnancy constituting to 54.3%. 21 patients had acute 
hepatitis B infection and 4 were presumptively taken as type E . Jaiswal 
SP and Naik G in 2001 and Jain A, Sharma JK in 1999 analysed various 
types of viral hepatitis during pregnancy. Their studies were shown 
below: 
Place Author Year HAV HBV HCV HDV HEV 
Noviral 
markers 
Indore Jaiswal SP 
Naik G Soni N 
2001 7% 19% 4% Nil 46% 24% 
 
New 
Delhi 
 
Jain A Sharma 
JK 
 
1999 
 
4% 
 
28% 
 
2% 
 
Nil 
 
42% 
 
18% 
  
Because of universal exposure during infancy and childhood, HAV 
infection is more common in children rather than in adults in developing 
countries like India. HDV always coinfects with Hepatitis B virus and 
cannot survive independently. Hence acute viral hepatitis in an adult in a 
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high prevalence country such as India is more likely to be HEV or HBV 
rather than HAV, HCV or HDV (Michael de Swiet, 2002). 
AGE : 
In the present study 45.7% of pregnant jaundiced women were 
between 20-24 years. This correlates with the study of ShethAbhay et al, 
1990, Devinder Kaur et al, 2001 and Kamala Jeyaram et al, 1988. 
This age group is having the maximum fertility rate and maximum 
number of deliveries. Early age of marriage in lower socioeconomic 
group due to illiteracy also contributes. (In Western Countries, only 30% 
are under 24 years). 
GRAVIDITY 
In this study 41.3% of patients were primigravida; It correlates 
with the study of Reddi Rani et al, 1993 and J.S. Chauhan et al, 1983 
(50%).Kamala Jeyaram et al, 1986 and Devinder Kaur et al, 2001 had 
showed only 30% incidence among primigravida. 
GESTATIONAL AGE 
93.5% of patients presented in 3rd trimester. This correlates well 
with the study of C.M. Alwani et al., 1986, Reddi Rani et al, 1993. 
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Increaed incidence in third trimester is probably due to excess nutritional 
stress in late pregnancy. 
SOCIOECONOMIC STATUS 
95% patients belonged to lower socioeconomic group in this study. 
This shows the influence of malnutrition, poor sanitation, water 
contamination, sexual abuse and poor health awareness in the 
development of jaundice as stressed by various authors. 
BIOCHEMICAL PARAMETERS 
In this study, 50% of maternal mortality were with serum bilirubin 
more than 15mg/dl. In the study of Chadda et al, 1983 majority of 
mortality occurred with serum billirubin level more than 15mg. 50% of 
maternal mortality were observed with serum transaminase levels 
between100-400IU/L in our study. Mortality also reported with low level 
and this is due to exhaustion by previous excessive release of 
transaminase (Issel Backer 1987). 
The prothrombin time is the most sensitive indicator of severity of 
liver dysfunction and hence the prognosis (Weinstein et al, 1982). A 
mildly elevated prothombin time usually indicates concurrent DIC 
whereas grossly elevated prothombin time signify significant hepatic 
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necrosis. Khuroo M.S. & Kamili in 2003 reported poor prognosis in 
patients with  prothombin time > 30 secs.  
COMPLICATIONS 
12 patients had anaemia. Among them 2 had severe anaemia (Hb 
<7gm%) and rest of them were between 7-10gm%. Among the 2 one died 
of variceal bleed. Among 6 pre-eclampsia patients 3 died. Anaemia and 
preeclampsia in a jaundiced patient further worsens the prognosis.2 
patients had PPH. Among 46 patients, 21 required blood transfusion. 
Alwani et al, 1985 reported 31% incidence of post portum haemorrhage 
in his studies. Our study has significantly lower incidence of PPH (25%). 
MODE OF DELIVERY 
41.3% of patients were delivered by LSCS for obstetric indications 
and 52.2% had labour natural. Since most were preterm, labour was 
easier. Mode of delivery did not influence maternal or fetal outcome. 
Early delivery by caesarian section to improve maternal and fetal survival 
and arresting the disease is recommended by Peter’s et al, 1967 and 
Burrough’s et al., 1983. However the risk of anaesthesia and bleeding 
due to coagulation abnormalities are the factors against it. 
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FETAL OUTCOME 
Among the total 43 patients, 24.3% had preterm delivery and 
75.7% had term deliveries. Sheth Abhay et al, 1999 reported 3% 
incidences of abortion and 55% preterm deliveries whereas Subodh 
Singh et al, 1991 reported 8% abortion and 64% preterm delivery. 
Total number of fetal death is 12. Among these 11 were preterm 
babies and only 2 was term. All neonatal deaths were because of 
prematurity and low birth weight. Prematurity and low birth weight as a 
cause of neonatal mortality was stressed by various authors (Jai Bagwan 
Singh, 1990, Subodh Singh et al, 1991, Devinder Kaur et al, 2001). 
Fetal loss by abortion and prematurity may be due to high fever and 
general debility associated with high viraemia. Perinatal mortality is 24%. 
MATERNAL OUTOME 
Out of 46 jaundiced pregnant women in this study, 8 women died. 
2 patients died of HELLP syndrome, 3 patients due to viral hepatitis, 2 
due to cirrhosis with portal hypertension and 1 due to acute fatty liver of 
pregnancy. 
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HELLP Syndrome 
HELLP Syndrome patients with jaundice constituted 12 patients, 
all of whom presented in late second and early 3rd trimester with severe 
hypertension. Weinstein et al, 1985 has reported the mean gestational 
age of presentation of HELLP syndrome was 33.6 wks.Among 12 
patients,8 normal term delivery, 3 were preterm delivery and one was 
intrauterine death. Perinatal mortality in this group was 50% ( 6 out of 
12). Weinsteinet al, 1985, Sibai et al, 1990 has reported a perinatal 
mortality rate of 60% in patients with HELLP syndrome. Higher perinatal 
mortality is due to prematurity. There was 2 maternal deaths in this 
group. One patient died due to DIC and other due to atonic pph .  Baha et 
al, 1990, reported a maternal mortality of 24% in his study, our study 
correlates with it (25%) 
Viral Hepatitis : 
Out of 25 patients due to viral hepatitis, there were 3 maternal 
deaths. One patient had acute hepatitis B infection and she presented with 
term IUD. Her pregnancy was terminated by Labour naturale. Her 
prothrombin time and bleeding time was prolonged. Another patient had 
combined hepatitis e infection and went in for fulminant hepatic failure 
and DIC. 
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Maternal mortality in this group was 37%. Maternal mortality 
among pregnant women with viral hepatitis was 14.3% whereas is non 
pregnant women it was 5.6% (De Swiet 2002). Age and parity did not 
reveal any significance. 
In the studies reported by Alwani et al, 1985 the cause of death 
among patients with viral hepatitis was hepatic coma in 2.4%, GI bleed in 
15%, Hepatorenal syndrome in 15%, PPH in 13% and Hepatic 
encephalopathy in 8%. Mirghani et al, 1992, observed more than 80% of 
deaths occurred in postpartum period. It is concluded that pregnancy is a 
risk factor which increases the mortality of viral hepatitis. 
Author Year Abortion 
Preterm 
delivery 
Perinatal 
Mortality 
Medha et al 1993 8.3% 20% 27% 
Padmaker 1986 8.3% 24% 30.9% 
Alwani et al 1985 11.9% 18% 29% 
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IHCP : 
 There were 3 patients with intrahepatic cholestasis of pregnancy in 
the study. All  presented with pruritis and Jaundice for 2-3 wks 
duration.There was no clinical evidence of viral hepatitis in these 
patients. One  patient had term delivery and another one was pre term,the 
other intrauterine death.  (Rioseco AJ, 1994) has reported an increased 
incidence of preterm labor (44% and 50% respectively) in IHCP patients.  
Cirrhosis and Portal Hypertension : 
 In 3 patients with cirrhosis and portal hypertension, 2 died, in one 
of them splenic rupture occurred and taken up for laparatomy,, baby IUD 
and mother died 2 hrs after splenectomy, the other patient was a known 
portal hypertension patient with oesophageal varices, banding done 4 
times,she was 11 wks pregnant when she was admitted with severe 
anemia and uncontrollable variceal bleeding. Inspite of multiple 
transfusions, she died. 
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MANAGEMENT 
 In patients with HELLP syndrome immediate termination of 
pregnancy once diagnosed is the treatment of choice, after stabilization of 
vitals. Strict control and frequent monitoring of BP is mandatory. Steroids 
also included in treatment.In IHCP, oral antihistaminic may provide some 
relief from pruritis, but UDCA is the preferred treatment. If patient is 
anicteric, pregnancy can be allowed to continue till term,otherwise 
pregnancy has to be terminated after completion of 36 weeks. 
 Management of patients with viral hepatitis was entirely 
symptomatic and supportive. It includes bed rest, high carbohydrate 
diet,glucose, vitamin B complex and IV dextrose. In none cases, 
termination of pregnancy was carried out prophylactically. Patients with 
chronic liver disease did not require any specific therapy except for 
frequent monitoring of liver function tests and coagulation profile. Blood 
and fresh frozen plasma were given when appropriate. 
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FETAL ANOMALIES 
 There was no congenital anomaly in the present study. Shah had 
reported that there is no convincing evidence that jaundice in the I 
trimester can cause fetal anomalies. So jaundice is not an indication for 
medical termination of pregnancies. 
DEVELOPMENT OF NEONATAL JAUNDICE 
 4 babies had only physiological jaundice. A jaundiced mother 
giving birth to a jaundiced baby is rare because in most cases, conjugated 
bilirubin is present to which placenta is impermeable (Sechar). 
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SUMMARY 
 A study was made on 46 jaundiced mothers who attended 
obstetrics and gynaecology department to find out the maternal morbidity 
and mortality rates for a period of 1 year. The results came as  
• Jaundice is more common in primigravida (41.3%). 
• Common in the age group of 21-25 years (45.7%). 
• The complications and incidence of jaundice is more common in 
third trimester (93.5%). 
• Most common etiology for jaundice is viral hepatitis 
(54.3%),second common is HELLP syndrome. 
• Death occurs most commonly due to DIC(37.5%). 
• 21 patients had multiple blood transfusions. 
• Out of 46 , 43 delivered and 3 undelivered, of the 43 cases 
37(86%) were live born and 6(14%) intrauterine death. 
• Of these 37 cases , 28 were term (75.7), 9 preterm (24.3%)., 20 
male babies (46.5%), 23 female babies (53.5%). 
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CONCLUSION 
 
1. According to my study, the incidence of jaundice complicating 
pregnancy in Coimbatore medical college is 3/1000. 
2. Jaundice in pregnancy is associated with high maternal and 
perinatal mortality 
3. Viral hepatitis is the commonest cause with about 25 cases. 
4. Among these 25 cases 21 had hepatitis B and the rest 4 had 
hepatitis E infection. 
5. The factors responsible for high maternal mortality in our country 
are malnutrition, poor personal hygiene, ignorance, delay in 
seeking medical advice, 
6. High serum bilirubin level is associated with high mortality levels. 
7. The incidence is high in primigravida and in third trimester 
8. Perinatal mortality is high in jaundice complicating pregnancy, the 
cause being prematurity and low birth weight. 
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MATERNAL OUTCOME IN JAUNDICE 
COMPLICATING PREGNANCY 
 
NAME:                                                          AGE:    IPNO: 
D.O.A: 
D.O.DELIVERY: 
D.O.DISCHARGE: 
PARITY: 
L.M.P:                                                                             E.D.D: 
COMPLAINTS: 
HOPI: 
PAST H/O: 
MENSTRUAL H/O:  
MARITAL H/O: 
OBSTETRIC H/O: 
ON EXAMINATION:   
CONSCIOUS/ORIENTED -                         ANAEMIC 
TEMPERATURE-                                         PEDAL EDEMA-                                         
ICTERIC – MILD/SEVERE 
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PR-                                         BP-                                CVS-                                    
RS- 
P/A- 
P/V- 
INVESTIGATIONS: 
HB% - 
URINE ALBUMIN 
            SUGAR  
            DEPOSIT 
            BS/BP 
BLOOD   SUGAR 
                UREA 
                S.CREATININE 
LFT       
  T.BILIRUBIN 
                  DIRECT 
             INDIRECT 
              SGOT 
              SGPT 
 
 
112 
 
              ALP 
              LDH 
PLATLET COUNT 
CLOTTING TIME 
BLEEDING TIME 
PROTHROMBIN TIME  
ACTIVATED PARTIAL THROMBOPLASTIN TIME 
VIRAL MARKERS: 
ULTRASOUND: 
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xg;g[jy;  gotk;; [ ; ;; [ ; ;; [ ; ; 
bgah; : 
ghypdk; :       taJ : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; kfg;ngW kUj;Jt 
Jiwapy; gl;l gapYk; khztp mth;fs; nkw;bfhs;Sk;  "k";rs; 
fhkhiy nehahy; jha;f;F Vw;gLk; cly;eyf;Fiwt[ kw;Wk; 
caph;nrjk;" Fwpj;j Ma;tpy; bra;Kiw kw;Wk; midj;J 
tptu';fisa[k; nfl;Lf; bfhz;L vdJ re;njf';fis 
bjspt[g;gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;Jld;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; 
btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. ve;j neuj;jpy; ,e;j Ma;tpypUe;J ehd; tpyfpf; 
bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;. 
 
,lk;  :      ifbahg;gk; / nuif 
ehs; : 
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KEY TO MASTER CHART 
U/A – Urine albumin. 
U BS/BP  –  Urine bile salt/bile pigment 
BT  –  Bleeding time 
CT – Clotting time 
PT  –  Prothrombin time 
HB – haemoglobin . 
SGOT – Serum glutamic oxaloacetic transaminase 
SGPT – Serum glutamic pyruvic transaminase 
SAP – Serum alkaline phosphatase. 
HBsAG – Hepatitis B surface antigen 
Anti HCV – Anti hepatitis c virus 
HEV – Hepatitis E virus. 
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1 Jerina Begam 28 primi 30 HELLP 2 wks 2+ + 3 8 28 9.8 3.8 lakh 7.3 98 131 171 - - - nil undelivered encephalopthy Death 
    
2 Maragatham 23 primi 39 Viral(HBV) 1 wk nil + 2 4 13 9.6 1.8 lakh 1.4 56 43 79 + - - nil LSCS NIL Recovered Term FCH 3 8/10 NIL 
3 Priya 24 primi 40 Viral(HBV) 3 days nil nil 2 3 12 11 2.1 lakh 2.2 75 73 266 + - - nil LN NIL Recovered Term FCH 3.1 9/10 NIL 
4 Prasanna 26 P1L1 
 
cirrhosis 
with portal 
hypertension 
3 days nil nil 3 4 12 8.2 82,000 1 22 26 441 - - - 1pc,4 ffp LSCS NIL Recovered 
    
5 Guna Sundari 21 primi 36 AFLP 1 day 1+ 2+ 2 10 26 14 52,000 14.2 92 152 412 - - - 4 pc,8 ffp LN Atonic PPH death Term MCH 2.7 6/10 Died 
6 Thilagavathy 21 G2P1L0 term viral(HEV) 1 day nil + 3 3 12 11 2.4 lakh 1.3 78 84 112 - - + nil LN NIL Recovered Term FCH 2.4 8/10 NIL 
7 Dhanalakshmi 32 G2P1L1 28 Viral(HBV) 2 days nil 2+ 4 4 20 10.9 84000 0.8 86 92 141 + - - 1pc,4 ffp LSCS NIL Recovered IUD MCH 
   
8 Shiji 20 G2A1 34 IHCP 2 days 1+ 1+ 3 6 20 14.5 1.79 lakh 17.1 179 440 193 - - - 2pc LN 
Vulval 
hematoma 
Recovered 
Alive FCH 
pre term 
1.8 6/10 NIL 
9 Sangeetha 24 
G3P1L1
A1 
term Viral(HBV) 1 day nil nil 2 5 26 10.6 2.11 lakh 3.8 142 112 186 + - - nil LN NIL Recovered 
Term Alive 
MCH 
2.7 8/10 NIL 
10 Shanthini 27 G2P1L1 32 HELLP 9 days 1+ + 1 8 20 11 60,000 11.6 43 52 257 - - - 2pc,4ffp LSCS NIL Recovered Pre term FCH 1.8 6/10 NIL 
11 Priyanka 20 primi term AFLP 2 days nil 2+ 3 7 13 8.7 53,000 12.3 109 79 385 - - - 1pc,4 ffp LN NIL Recovered IUD MCH 2.7 
  
12 Gandhimathi 32 G2P1L1 term Viral(HBV) 8 days nil nil 2 4 12 10.5 1.7 lakh 1.1 26 28 140 + - - nil LSCS NIL Recovered Term MCH 3.6 8/10 NIL 
13 
Ruth 
Priyadharshini 
24 P1L1 
day of 
delivery 
HELLP 1 day nil nil 3 8 13 7.9 96,000 8.7 150 366 230 - - - 2pc LN NIL Recovered Term FCH 2.4 7/10 NIL 
14 Shanthi 29 
G5P3L1
A1 
term HELLP 2 days 1+ nil 4 4 11 11 70,000 7.8 260 272 1176 - - - 2pc LSCS NIL Recovered Term FCH 2.8 6/10 Died 
15 Banumathy 31 primi term viral(HBV) 1 day nil 2+ 3 3 12 12 2 lakh 10.8 116 181 227 + - - nil LN NIL Recovered Term FCH 3.1 8/10 NIL 
16 
Baby 
Kaneeshwari 
26 primi term Viral(HBV) 2 days nil 1+ 2 4 13 10 1.11 lakh 6.4 21 18 123 + - - nil LSCS NIL Recovered Term FCH 3.2 8/10 NIL 
17 Sundarammal 27 primi term viral(HBV) 1 day nil 1+ 2 7 13 11 3.45 lakh 8.3 39 45 535 + - - nil LSCS NIL Recovered Term MCH 2 7/10 Died 
18 
Chinna 
Marathal 
33 G3P2L2 36 HELLP 1 week 2+ nil 3 8 13 5.1 7000 2.2 96 84 210 - - - 
4pc,10plt, 
12ffp 
VBAC DIC Death preterm mch 1.8 7/10 Died 
19 Anbuselvi 22 
G5P1L1
A3 
37 Viral(HBV) 1 day nil nil 3 7 12 10.4 1.9 lakh 1.6 31 27 130 + - - nil LN NIL Recovered 
Alive MCH 
term 
2.6 8/10 NIL 
20 Bhuvaneswari 26 primi 37 
cirrhosis 
with portal 
hypertension 
1wk nil nil 4 7 13 10.1 3.4 lakh 0.9 98 72 112 - - - 4pc,10ffp LSCS splenic rupture Death IUD MCH 1.9 
  
21 Devi 29 G3P2L1 29 IHCP 1 day nil nil 2 6 12 11.8 2.21 lakh 18.3 110 106 152 - - - nil LN NIL Recovered IUD MCH 1.2 
  
22 Pushpa 21 
G9P2L1
A6 
38 IHCP 2 wks nil nil 3 7 13 10 2.3 lakh 4.6 49 55 311 - - - nil LSCS NIL Recovered Term FCH 2.1 7/10 NIL 
23 Madhuri Devi 23 G2P1L0 40 Viral(HBV) - nil nil 2 4 12 13.5 69,000 3.4 24 26 86 + - - nil LSCS NIL Recovered Term FCH 2.6 8/10 NIL 
24 Kalishrani 22 primi 28 viral(HBV) - nil nil 3 7 14 7.8 1.8 lakh 8.2 299 210 814 + - - nil LN NIL Recovered 
Pre term 
MCH 1.8 kg 
1.2 7/10 Died 
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25 Chellammal 20 primi term HELLP 3 days nil nil 5 8 20 8 92,000 11.1 86 124 298 - - - 2pc,10ffp LN NIL Recovered Term FCH 2.8 8/10 Died 
26 Malathy 26 G2A1 term Viral(HBV) 4 days nil nil 3 7 18 10.4 2.87 lakh 2.6 29 27 135 + - - nil LSCS NIL Recovered Term FCH 3.6 9/10 NIL 
27 Kalamani 24 G2P1L1 term HELLP 2 days nil nil 2 3 20 5.1 32,000 7.1 34 37 90 - - - 1pc, 2plt LN Atonic PPH Death Term FCH 2.4 7/10 NIL 
28 Gomathi 25 G3P2L2 term HELLP 4 days nil nil 3 6 24 7.6 90,000 6.7 128 114 370 - - - 
2pc,6plt, 
4ffp 
LSCS NIL Recovered Term MCH 2.6 8/10 NIL 
29 Selvi 34 G2P1L1 term HELLP 1 wk 2+ nil 2 5 20 8.1 76,000 5.8 270 240 860 - - - 2pc,2plt LSCS NIL Recovered Term MCH 2.5 7/10 NIL 
30 Lavanya 26 primi 34 Viral(HBV) 2 wks nil + 3 5 18 10.1 1.86 lakh 4.4 178 264 1176 + - - nil LN NIL Recovered 
Pre Term 
FCH 
1.7 6/10 Died 
31 Saranya 23 primi term viral(HEV) 1 wk nil 2+ 3 10 30 12.6 4.22 lakh 15.7 123 161 593 - - + 10ffp LN DIC Death 
Term IUD 
MCH 
3 
  
32 Kanniyammal 27 primi term Viral(HBV) 2 days nil nil 3 6 20 11.8 2.18 lakh 2.4 56 58 114 + - - nil LN NIL Recovered Term MCH 2.9 8/10 NIL 
33 Rajeswari 25 G6P5L3 31 Viral(HBV) 1 wk nil nil 3 7 17 9.4 1.88 lakh 7 112 88 199 + - - 1pc, LN Atonic PPH Recovered 
Pre Term 
FCH 
1.9 7/10 
Recover
ed 
34 Prema 28 G2P1L1 32 Viral(HBV) 1 day nil 1+ 4 6 13 10.2 2.86 lakh 2.4 186 172 286 + - - nil LSCS NIL Recovered 
Pre term 
MCH 
1.9 8/10 
Recover
ed 
35 Radha 31 G2P1L1 29 viral(HBV) 2 wks nil nil 2 4 13 12.8 1.44 lakh 2.4 26 28 91 + - - nil LN NIL Recovered 
Pre Term 
Alive MCH 
1.6 6/10 
Recover
ed 
36 kalyani 26 primi 11 
cirrhosis 
with portal 
hypertension 
1 month nil + 3 16 30 2 1.86 lakh 18.1 
178
6 
186
6 
2500 - - - 1pc,2ffp undelivered Variceal Bleed Died 
    
37 Chithra 24 G3P2L2 34 viral(HBV) 1 day nil nil 1 5 12 10.6 2.81 lakh 7.6 88 92 126 + - - nil LN Prerenal ARF Recovered Pre term FCH 1.8 7/10 NIL 
38 Ramathal 20 primi 38 AFLP 3 days 1+ nil 4 6 20 11.2 79,000 4.8 72 86 119 - - - nil LSCS DIC Recovered Term MCH 2.7 8/10 NIL 
39 Bhooma 25 G2P1L1 39 Viral(HBV) 1 day nil nil 3 7 13 12.1 2.71 lakh 0.9 26 28 40 + - - nil LN NIL Recovered Term FCH 2.5 7/10 NIL 
40 Devi 23 primi 38 Viral(HBV) 3 days nil nil 2 6 12 10.6 1.98 lakh 2.4 28 27 41 + - - nil LSCS NIL Recovered Term MCH 2.8 8/10 NIL 
41 Lakshmi 24 G3A2 35 viral(HEV) 2 days nil nil 3 6 13 11.2 2.25 lakh 3.6 72 78 121 - - + nil Undelivered NIL Recovered 
    
42 Kala 26 G2P1L1 40 HELLP 1 day 1+ nil 3 5 18 10.8 66,000 2.1 86 88 562 - - - 2ffp, 2plt LSCS DIC Recovered Term FCH 3 8/10 NIL 
43 Shylu Priya 25 G2A1 38 Viral(HBV) 2 days nil nil 2 6 12 9.4 1.72 lakh 2.6 72 76 112 + - - nil LN NIL Recovered Term MCH 2.2 7/10 NIL 
44 Sumathi 20 primi 37 HELLP 1 day 1+ nil 1 7 15 9.8 72,000 3.1 56 56 189 - - - 
1pc,2plt, 
4ffp 
LN NIL Recovered Term FCH 2.8 8/10 NIL 
45 Dhanalakshmi 22 primi 39 HELLP 1 day 1+ nil 4 6 14 9.7 88,000 2.9 70 66 163 - - - 2plt,4 ffp LSCS NIL Recovered Term FCH 2.3 7/10 NIL 
46 Latha 21 G5A4 34 viral(HEV) 1 day nil 2+ 3 5 28 11 1.11 lakh 13.6 88 186 440 - - + 8ffp LN DIC Death 
Term FCH 
IUD 
2.9 
  
 
